Sifalimumab, a Human Anti–Interferon‐α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose‐Escalation Study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Sifalimumab, a Human Anti–Interferon‐α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose‐Escalation Study

Published:2013-03-28 Issue:4 Volume:65 Page:1011-1021
ISSN:0004-3591
Container-title:Arthritis & Rheumatism
language:en
Short-container-title:Arthritis & Rheumatism

Author:

Petri Michelle¹,Wallace Daniel J.²,Spindler Alberto³,Chindalore Vishala⁴,Kalunian Kenneth⁵,Mysler Eduardo⁶,Neuwelt C. Michael⁷,Robbie Gabriel⁸,White Wendy I.⁸,Higgs Brandon W.⁸,Yao Yihong⁸,Wang Liangwei⁸,Ethgen Dominique,Greth Warren⁸

Affiliation:

1. Johns Hopkins University School of Medicine, Baltimore, Maryland

2. Cedars‐Sinai Medical Center and David Geffen School of Medicine, University of California, Los Angeles

3. Centro Medico Privado de Reumatologia, Tucumán, Argentina

4. Pinnacle Research Group, Anniston, Alabama

5. University of California at San Diego, La Jolla

6. Organización Médica de Investigación, Buenos Aires, Argentina

7. East Bay Rheumatology Research Institute, San Leandro, California

8. MedImmune, LLC, Gaithersburg, Maryland

Publisher

Wiley

Subject

Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.37824

Reference36 articles.

1. Guidelines for referral and management of systemic lupus erythematosus in adults

2. Systemic Lupus Erythematosus

3. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics

4. The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosus

5. Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus?

Cited by 220 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interferonopathies: From concept to clinical practice;Best Practice & Research Clinical Rheumatology;2024-08

2. Monoclonal antibodies targeting interleukins for systemic lupus erythematosus: updates in early clinical drug development;Expert Opinion on Investigational Drugs;2024-07-09

3. Biomarkers Associated with Drugs for the Treatment of Lupus Nephritis;Biomolecules;2023-10-31

4. 2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice;Annals of the Rheumatic Diseases;2023-03-01

5. Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider;RMD Open;2023-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3